Business
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 Management to host conference call today, August 8, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the second quarter and year-to-date period ended June 30, 2024. “The XDEMVY launch continues building a strong foundation to serve patients and doctors with a high value new category of medicine, with impressive quarter-over-quarter growth and robust payer coverage, including additional Medicare coverage – making it one of the most successful eye care launches to date,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “We believe we’re just scratching the surface of XDEMVY’s potential and expect the expansion of our sales force and a planned new direct-to-consumer campaign to continue accelerating our growth and the potential ability to reach millions of patients with Demodex blepharitis.” Recent Business Highlights The commercial launch of XDEMVY continues to underscore the establishment of a new potential blockbuster category in eye care. In the second quarter, the Company: Generated $40.8 million in XDEMVY net product sales, a 65% increase over Q1 2024Substantially improved gross-to-net discount to 44% from 55% in Q1 2024Delivered more than 37,000 bottles of XDEMVY to patientsAccelerated Eye Care Professional (ECP) adoption – approximately 11,000 ECPs, as of August 7, 2024, have started patients on XDEMVY launch-to-date with more than 60% prescribing XDEMVY to multiple patients Significantly expanded payer coverage of XDEMVY among commercial, and now Medicare payers Secured several new contracts in the second quarter, including another major commercial plan with more than 20 million covered lives, and one major Medicare paye...